Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study
Abstract Background Although triptorelin is increasingly used in China for biochemical castration, its effects on primary prostate cancer symptoms remain unclear. This study aimed to assess the prevalence of lower urinary tract symptoms (LUTS) in Chinese prostate cancer patients and the effectivenes...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-03-01
|
Series: | BMC Urology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12894-018-0337-4 |
id |
doaj-02905217b69e4c30ab53889f8c5a23f1 |
---|---|
record_format |
Article |
spelling |
doaj-02905217b69e4c30ab53889f8c5a23f12020-11-24T23:59:38ZengBMCBMC Urology1471-24902018-03-011811810.1186/s12894-018-0337-4Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective studyLe-Ye He0Ming Zhang1Zhi-Wen Chen2Jian-Lin Yuan3Ding-Wei Ye4Lu-Lin Ma5Hui Wei6Jiang-Gen Yang7Shan Chen8Ben Wan9Shu-Jie Xia10Zhi-Liang Weng11Xiang-Bo Kong12Qiang Wei13Feng-Shuo Jin14Xiang-Hua Zhang15Wei-Qing Qian16Shu-Sheng Wang17Ying-He Chen18Hong-Shun Ma19Ying-Hao Sun20Xu Gao21Department of Urology, Third Xiangya Hospital, Central South UniversityDepartment of Urology, the Second Hospital of Jilin UniversityDepartment of Urology, Southwest Hospital, Third Military Medical UniversityDepartment of Urology, Xijing Hospital, the Fourth Military Medical UniversityDepartment of Urology, Fudan University Shanghai Cancer CenterDepartment of Urology, Peking University Third HospitalDepartment of Urology, Shenzhen Zhongshan Urological HospitalDepartment of Urology, Shenzhen People’s Hospital, The Second Clinical Medical College of Ji’nan UniversityDepartment of Urology, Beijing Tongren Hospital Capital Medical UniversityDepartment of Urology, Beijing Hospital of the Ministry of HealthDepartment of Urology, Shanghai First People’s Hospital Affiliated to Shanghai Jiaotong UniversityDepartment of Urinary Surgery, the First Affiliated Hospital of Wenzhou Medical CollegeDepartment of Urology, China-Japan Union Hospital, Jilin UniversityDepartmentof Urology, West China Hospital, Sichuan UniversityDepartment of Urinary Surgery, Institute of Surgery Research, Daping Hospital, Third Military Medical UniversityDepartment of Urology, Shougang Hospital of Peking UniversityDepartment of Urology, Huadong Hospital, Fudan UniversityDepartment of Urology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou University of Chinese MedicineDepartment of Urology, Second Affiliated Hospital of Wenzhou Medical CollegeDepartment of Urology, Tianjin First Central HospitalDepartment of Urology, Changhai Hospital, Second Military Medical UniversityDepartment of Urology, Changhai Hospital, Second Military Medical UniversityAbstract Background Although triptorelin is increasingly used in China for biochemical castration, its effects on primary prostate cancer symptoms remain unclear. This study aimed to assess the prevalence of lower urinary tract symptoms (LUTS) in Chinese prostate cancer patients and the effectiveness of triptorelin on LUTS. Methods In this 48-week multicenter, non-interventional, prospective study, we enrolled patients with locally advanced or metastatic prostate cancer. Patients received triptorelin (15 mg) intramuscularly at baseline and at weeks 12, 24, and 36 with symptom assessment using the International Prostate Symptoms Score (IPSS). The primary endpoints were the prevalence of LUTS at baseline per IPSS categories and the percentage of patients with moderate to severe LUTS (IPSS > 7) at baseline, having at least a 3-point reduction of IPSS score at week 48. Results A total of 398 patients were included; 211 (53.0%) and 160 (40.2%) among them had severe and moderate LUTS, respectively. Of the patients with IPSS scores available at baseline and at week 48 (n = 213), 81.2% achieved a reduction in IPSS of at least 3 points. Of the patients with moderate to severe LUTS at baseline and IPSS scores available at baseline and at week 48 (n = 194), 86.6% achieved a total IPSS reduction of at least 3 points. Conclusions The vast majority of Chinese patients with locally advanced or metastatic prostate cancer scheduled to receive triptorelin as part of their standard treatment have severe or moderate LUTS. Triptorelin therapy resulted in sustained improvement of LUTS in these patients.http://link.springer.com/article/10.1186/s12894-018-0337-4Prostate cancerLower urinary tract symptoms (LUTS)PrevalenceInternational prostate symptoms score (IPSS)Triptorelin |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Le-Ye He Ming Zhang Zhi-Wen Chen Jian-Lin Yuan Ding-Wei Ye Lu-Lin Ma Hui Wei Jiang-Gen Yang Shan Chen Ben Wan Shu-Jie Xia Zhi-Liang Weng Xiang-Bo Kong Qiang Wei Feng-Shuo Jin Xiang-Hua Zhang Wei-Qing Qian Shu-Sheng Wang Ying-He Chen Hong-Shun Ma Ying-Hao Sun Xu Gao |
spellingShingle |
Le-Ye He Ming Zhang Zhi-Wen Chen Jian-Lin Yuan Ding-Wei Ye Lu-Lin Ma Hui Wei Jiang-Gen Yang Shan Chen Ben Wan Shu-Jie Xia Zhi-Liang Weng Xiang-Bo Kong Qiang Wei Feng-Shuo Jin Xiang-Hua Zhang Wei-Qing Qian Shu-Sheng Wang Ying-He Chen Hong-Shun Ma Ying-Hao Sun Xu Gao Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study BMC Urology Prostate cancer Lower urinary tract symptoms (LUTS) Prevalence International prostate symptoms score (IPSS) Triptorelin |
author_facet |
Le-Ye He Ming Zhang Zhi-Wen Chen Jian-Lin Yuan Ding-Wei Ye Lu-Lin Ma Hui Wei Jiang-Gen Yang Shan Chen Ben Wan Shu-Jie Xia Zhi-Liang Weng Xiang-Bo Kong Qiang Wei Feng-Shuo Jin Xiang-Hua Zhang Wei-Qing Qian Shu-Sheng Wang Ying-He Chen Hong-Shun Ma Ying-Hao Sun Xu Gao |
author_sort |
Le-Ye He |
title |
Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study |
title_short |
Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study |
title_full |
Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study |
title_fullStr |
Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study |
title_full_unstemmed |
Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study |
title_sort |
triptorelin relieves lower urinary tract symptoms in chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study |
publisher |
BMC |
series |
BMC Urology |
issn |
1471-2490 |
publishDate |
2018-03-01 |
description |
Abstract Background Although triptorelin is increasingly used in China for biochemical castration, its effects on primary prostate cancer symptoms remain unclear. This study aimed to assess the prevalence of lower urinary tract symptoms (LUTS) in Chinese prostate cancer patients and the effectiveness of triptorelin on LUTS. Methods In this 48-week multicenter, non-interventional, prospective study, we enrolled patients with locally advanced or metastatic prostate cancer. Patients received triptorelin (15 mg) intramuscularly at baseline and at weeks 12, 24, and 36 with symptom assessment using the International Prostate Symptoms Score (IPSS). The primary endpoints were the prevalence of LUTS at baseline per IPSS categories and the percentage of patients with moderate to severe LUTS (IPSS > 7) at baseline, having at least a 3-point reduction of IPSS score at week 48. Results A total of 398 patients were included; 211 (53.0%) and 160 (40.2%) among them had severe and moderate LUTS, respectively. Of the patients with IPSS scores available at baseline and at week 48 (n = 213), 81.2% achieved a reduction in IPSS of at least 3 points. Of the patients with moderate to severe LUTS at baseline and IPSS scores available at baseline and at week 48 (n = 194), 86.6% achieved a total IPSS reduction of at least 3 points. Conclusions The vast majority of Chinese patients with locally advanced or metastatic prostate cancer scheduled to receive triptorelin as part of their standard treatment have severe or moderate LUTS. Triptorelin therapy resulted in sustained improvement of LUTS in these patients. |
topic |
Prostate cancer Lower urinary tract symptoms (LUTS) Prevalence International prostate symptoms score (IPSS) Triptorelin |
url |
http://link.springer.com/article/10.1186/s12894-018-0337-4 |
work_keys_str_mv |
AT leyehe triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT mingzhang triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT zhiwenchen triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT jianlinyuan triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT dingweiye triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT lulinma triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT huiwei triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT jianggenyang triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT shanchen triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT benwan triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT shujiexia triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT zhiliangweng triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT xiangbokong triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT qiangwei triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT fengshuojin triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT xianghuazhang triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT weiqingqian triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT shushengwang triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT yinghechen triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT hongshunma triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT yinghaosun triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy AT xugao triptorelinrelieveslowerurinarytractsymptomsinchineseadvancedprostatecancerpatientsamulticenternoninterventionalprospectivestudy |
_version_ |
1725446977615822848 |